Background-Contemporary adjunctive pharmacology and revascularization strategies have improved the prognosis of patients with acute coronary syndromes (ACSs). We sought to identify the clinical and angiographic predictors of cardiac ischemic events in patients with ACSs treated with an early invasive strategy. Methods and Results-Multivariable logistic regression was used to analyze the relation between baseline characteristics and 30-day and 1-year composite ischemia (death, myocardial infarction, or unplanned revascularization) among the 6921 ACS patients included in the prespecified angiographic substudy of the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial. Of the 6921 patients, 3826 (55.3%) were treated with percutaneous coronary intervention, 755 (10.9%) with coronary artery bypass grafting, and 2340 (33.8%) with medical therapy. Composite ischemia occurred in 595 (8.6%) patients at 30 days and in 1153 (17.4%) at 1 year. Renal insufficiency, biomarker elevation, ST-segment deviation, nonuse of aspirin or thienopyridine, insulin-treated diabetes, older age, baseline lower hemoglobin value, history of percutaneous coronary intervention, and current smoking were independently associated with 30-day or 1-year ischemic events. Angiographic characteristics predicting ischemic events included number of diseased vessels, moderate/severe calcification, worst percent diameter stenosis, jeopardy score, lower left ventricular ejection fraction, lesion eccentricity, and thrombus. With use of receiver operating characteristic methodology, the c statistic improved for the predictive model by adding angiographic to clinical parameters for the 30-day composite ischemia (from 0.62 to 0.68) and myocardial infarction (from 0.64 to 0.71) and 1-year composite ischemia (from 0.61 to 0.65) and myocardial infarction (from 0.63 to 0.69) end points. Conclusions-Among ACS patients managed with an early invasive strategy, baseline angiographic markers of disease burden, calcification, lesion severity, lower left ventricular ejection fraction, and morphological characteristics provided important added independent predictive value for 30-day and 1-year ischemic outcomes, beyond the well-recognized clinical risk factors. These findings emphasize the prognostic importance of the diagnostic angiogram in the risk stratification of patients presenting with ACSs. Clinical Trial Registration-URL: http://clinicaltrials.gov. Unique identifier: NCT00093158. (Circ Cardiovasc Interv. 2010;3:308-316.) Key Words: acute coronary syndromes Ⅲ angiography Ⅲ early invasive strategy Ⅲ prognosis Ⅲ predictor C ontemporary practice for the management of moderateand high-risk acute coronary syndromes (ACSs) has improved in the last decade and in general should include an early invasive strategy and concomitant use of evidence-based medications, such as antithrombotic and antiplatelet therapy, angiotensin-converting enzyme inhibitors, statins, and ␤-blockers. 1,2 Although clinical predictors of short-and long-term ischemic outcomes among patients with ACSs have been extensively studied, whether baseline angiographic characterization of such patients
undergoing an early invasive approach adds predictive insight is not well defined. [3] [4] [5] [6] Clinical Perspective on p 316
The aim of this study was to examine the clinical and angiographic factors impacting ischemic events, including death, myocardial infarction (MI), and unplanned revascularization, at 30 days and 1 year among patients enrolled in the angiographic substudy of the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial. [7] [8] [9] Methods
Study Population and Design
The design and results of the ACUITY trial have been previously published. [7] [8] [9] In summary, patients Ͼ18 years of age were eligible if they presented within 24 hours of an episode of ischemic chest pain lasting at least 10 minutes and had either new ST-segment depression or transient elevation of at least 1 mm; elevations in the troponin I, troponin T, or creatine kinase MB (CKMB) levels; known coronary artery disease (CAD); or all 4 other variables predicting Thrombolysis in Myocardial Infarction (TIMI) risk scores for unstable angina. Patients with ST-segment elevation, shock, or a calculated creatinine clearance rate of Ͻ30 mL/min were excluded.
Eligible patients were randomly assigned to treatment with 1 of 3 antithrombotic regimens: heparin (unfractionated or enoxaparin at site discretion) plus a glycoprotein (GP) IIb/IIIa inhibitor, bivalirudin plus a GP IIb/IIIa inhibitor, or bivalirudin monotherapy. The antithrombin and antiplatelet drug dosing regimens have been previously described. 9 Per protocol, coronary angiography was required within 72 hours of randomization, with subsequent triage to treatment with percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), or medical management based on physician decision. Use of other medications was recommended in accordance with published guidelines. 1, 2 The study was approved by the institutional review board or ethics committee at each participating center, and all patients signed a written, informed consent.
Angiographic Analysis
The angiographic substudy of ACUITY included the first 7000 consecutive, randomized, US patients, of whom 6921 had interpretable angiograms. Angiographic analyses were performed at the Cardiovascular Research Foundation, New York, NY, as previously described. 10, 11 All angiograms were reviewed by an independent core laboratory for complete 3-vessel assessment of extent and burden (total length of lesions in mm Ͼ30% diameter stenosis) of CAD as well as baseline and final lesion and flow characteristics. The presence of coronary disease was defined as a stenosis of at least 30% in a major epicardial vessel. Qualitative morphological assessment included calcification, defined as readily apparent radio-opaque densities seen within the arterial wall anywhere in the coronary tree. Coronary thrombus was defined as an intraluminal filling defect or an area of contrast staining noted within the stenosis. Ulceration was identified for lesions noted to have a small crater or lumen flap. Aneurysm was defined by a focal arterial dilatation of Ͼ50% relative to the normal adjacent reference segment. Left ventricular ejection fraction (LVEF) was measured on the basis of left ventriculography.
End Points and Definitions
The combined ischemic end point included all-cause death, MI, or unplanned revascularization. The primary end point definitions have previously been detailed. 9 The definition of MI took into consideration the presence or absence of non-ST-segment-elevation MI at baseline, its time of occurrence, and its association with PCI, CABG, or medical treatment. In patients with unstable angina (without non-ST-segment-elevation MI) before angiography or triaged to medical treatment, an MI was defined as any elevation of troponin or CKMB greater than the upper limit of normal (ULN) (or CKϾULN in the absence of MB determination). In patients with non-STsegment-elevation MI before angiography or under medical treatment in whom the elevated troponin or CKMB (or CK) levels were documented to be decreasing or had returned to normal, diagnosis of a second infarction required (1) a new elevation of troponin or CKMB ϾULN (or CK ϾULN in the absence of MB determination) if the troponin or CKMB (or CK) level had returned to ϽULN or (2) an increase by Ͼ50% above the previous nadir level if the troponin or CKMB (or CK) level had not returned to ϽULN. In patients with non-ST-segment elevation MI at presentation in whom the peak troponin or CKMB (or CK) had not yet been reached, diagnosis of a second infarction required (1) recurrent chest pain Ն30 minutes or (2) new ECG changes consistent with MI and (3) the next troponin or CKMB (or CK) level measured Ϸ8 to 12 hours after the event was elevated by at least 50% above the previous level. In patients treated with PCI, MI was defined as (1) any CKMB (or CK) Ն3 times the ULN within 24 hours after PCI that was also increased by at least 50% with respect to the most recent pre-PCI levels or new, significant (Ն0.04 second) Q waves in 2 or more contiguous ECG leads with CKMB (or CK) ULN if the elevated CKMB or CK levels were falling or normal; (2) recurrent chest pain Ն30 minutes or new ECG changes consistent with a second MI and the next CKMB (or CK level) measured Ϸ8 to 12 hours after the event to be elevated by at least 50% above the previous level or new, significant (Ն0.04 second) Q waves in 2 or more contiguous ECG leads if the patients had non-ST-segment elevation MI at baseline but the peak CKMB (or CK) had not yet been reached. In patients undergoing CABG, a diagnosis of MI required (1) any CKMB Ն10 times the ULN (or CK Ն10 times the ULN in the absence of MB determination) within 24 hours of CABG and increased by at least 50% with respect to the most recent pre-CABG levels or (2) any CKMB Ն5 times the ULN (or CK Ն5 times the ULN in the absence of MB determination) within 24 hours of CABG and increased by at least 50% with respect to the most recent pre-CABG levels and new, significant (Ն0.04 second) Q waves in Ն2 contiguous ECG leads. All end points were adjudicated by a Clinical Events Committee blinded to treatment assignment.
Statistical Analyses
All analyses were based on intention to treat. Categorical values were compared by 2 or Fisher's exact test. Probability values for continuous variables were calculated by the nonparametric Wilcoxon test. One-year follow-up analysis was performed with time-to-event methodology and compared with the log-rank test. For patients experiencing Ͼ 2 events, only the first or most important (death) event was considered in the analysis. The probability values are given for informational purposes. Multivariable logistic-regression analyses were performed to evaluate the relations between baseline characteristics and the occurrence of death, MI, and composite ischemia at 30 days, between 30 days and 1 year, and at 1 year. The following list of covariates was used to determine multivariable predictors; age, male sex, diabetes, insulin-treated diabetes, hypertension, hyperlipidemia, current smoking, previous MI, previous PCI, previous CABG, renal insufficiency (creatine clearance Ͻ60 mL/min), baseline hemoglobin level, treatment group comparison (bivalirudin plus a GP IIb/IIIa inhibitor vs heparin plus a GP IIb/IIIa inhibitor and bivalirudin alone vs heparin plus a GP IIb/IIIa inhibitor), aspirin at discharge, thienopyridine at discharge, statin at discharge, LVEF, extent of disease, number of diseased vessels, jeopardy score, baseline TIMI flow grade 0/1, baseline blush 0/1, eccentricity, ulcerated, aneurysm, ectasia, moderate/severe calcification, thrombus, collaterals, and worst percent diameter stenosis of any coronary lesion. 12 Multivariable logistic models used stepwise selection methods with entry/stay criteria of 0.1/0.1. The probability values, odds ratios (ORs), and corresponding 2-sided 95% CIs for predictors are presented. To compare the relative value of a predictive model based on clinical factors only versus 1 based on clinical and angiographic factors; we used receiver operating characteristic methodology and the c statistic for 30-day and 1-year end points of composite ischemia, MI, and death. All statistical analyses were performed with SAS version 8.2 (SAS Institute Inc, Cary, NC).
Results
Baseline characteristics of the population are described in Table 1 . High-risk patients (biomarker elevation or STsegment deviation) comprised 62.1% of the cohort. Overall, aspirin was used in 98.4% of patients and a thienopyridine in 55.6% before angiography. Baseline angiographic data ranged from 3-vessel disease in 44.2% to no significant stenoses in 9.3% of patients. Baseline TIMI flow grade 0/1 was identified in 22.2%, moderate or severe calcification was present in 34.1%, and thrombus was detected in 15.7% of the population.
Serial Clinical Outcomes After Randomization
Overall, 595 (8.6%) of the 6921 patients had an ischemic event within 30 days after randomization, with an additional 558 (9.5%) occurring between 30 days and 1 year, for an overall 1-year composite ischemic event rate of 17.4% (nϭ1153; Table 2 ). At 1 year, there were a total of 228 deaths (3.4%). Of these, 88 (1.3%) occurred in the first 30 days and 140 (2.1%) in the period from 30 days to 1 year. MI occurred in 570 (8.5%) patients within 1 year after randomization. Of these 570 patients, 425 (74.6%) had an MI within 30 days after randomization, which were mostly non-Q-wave MIs. A total of 614 (9.6%) patients required unplanned revascularization within 1 year, with 5.2% in the target vessel and 4.8% in a different territory (nontarget vessel revascularization). The rate of patients requiring unplanned revascularization was higher among those treated with PCI compared with treatment with CABG or medical management.
Baseline Characteristics of Patients With and Without Composite Ischemia
The univariable relations between baseline clinical characteristics and composite ischemia at 30 days and 1 year are shown in Table 3 . Renal insufficiency was strongly correlated with 30-day composite ischemia, as were older age, male sex, and high-risk status (positive cardiac biomarkers or ST-segment deviation). Body weight, previous PCI, and previous CABG were weaker predictors. Most predictors of 30-day composite ischemia also predicted composite ischemia at 1 year, including renal insufficiency and treatment strategy. In addition, diabetes, insulin-treated diabetes, hypertension, hyperlipidemia, and previous MI also predicted 1-year composite ischemia. Table 4 shows the univariable relations between angiographic parameters and 30-day and 1-year composite ischemia. Important angiographic predictors of 30-day and 1-year composite ischemia included measures of plaque burden (ie, number of lesions per patient or jeopardy score), and a number of qualitative factors, such as TIMI flow grade, blush grade, ectasia, ulceration, eccentricity, and thrombus, were all univariate predictors of ischemia.
The composite ischemic event rates at 1 year were 4.7% in patients with no diseased vessels, 13.1% in those with 1 diseased vessel, 16.9% in those with 2 diseased vessels, and 22.1% in those with 3 diseased vessels (Figure, A) . The rates of composite ischemia at 1 year ranged from 14.7% in patients with no vessels with a calcified lesion to 20.0%, 24.4%, and 25.3% with 1, 2, and 3 vessels with a calcified lesion, respectively (Figure, B) . Kaplan-Meier analysis revealed significant differences in outcomes according to the number of diseased vessels and the number of the calcified vessels ( Figure, A and B ).
Multivariable Analysis of Ischemic Events
A stepwise logistic-regression analysis was performed to evaluate the impact of baseline characteristics on death, MI, and composite ischemia at 30 days and 1 year ( Table 5 ). Independent predictors of death at 30 days and 1 year included nonuse of aspirin, older age, LVEF, and jeopardy score. In addition, 30-day death was independently associated with lower baseline hemoglobin, nonuse of thienopyridine, and ST-segment deviation, whereas 1-year death was correlated with insulin-treated diabetes, current smoker, and moderate/severe calcification.
Characteristics independently associated with higher rates of MI at 30 days and 1 year included biomarker elevation, number of diseased vessels, renal insufficiency, and moderate/severe calcification. Additionally, higher rates of 30-day MI were correlated with jeopardy score and eccentricity, whereas 1-year MI was correlated with nonuse of aspirin, 
Comparison of Predictive Models With and Without Angiographic Parameters
With receiver operating characteristic methodology, the area under the receiver operating characteristic curve, or c statistic, improved for the predictive model that included the angiographic and clinical predictors compared with clinical predictors only for 30-day composite ischemia (from 0.62 to 0.68) and MI (from 0.64 to 0.71) and 1-year composite ischemia (from 0.61 to 0.65) and MI (from 0.63 to 0.69) end points. The addition of angiographic to the clinical predictors did not change the c statistic for either 30-day mortality (0.83 for both models) or 1-year mortality (0.75 for both models).
Discussion
The angiographic substudy of the ACUITY trial is the largest study of moderate-and high-risk ACS patients (Nϭ6921) triaged with an early invasive diagnostic catheterization that incorporated an extensive systematic, independent, blinded, core laboratory evaluation. Among the 6921 patients undergoing angiographic analysis, 3826 patients (55.3%) were treated with PCI, 755 (10.9%) with CABG, and 2340 (33.8%) 
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with medical therapy. The strategy referral rates in ACUITY are similar to those reported in prior studies. [13] [14] [15] [16] Although an early invasive strategy with angiographic triage is recommended for high-risk ACS patients, 1,2 the added predictive value of the baseline angiogram in riskstratifying patients has not been systematically defined. Thus, this ACUITY substudy provides a unique opportunity to examine the expanded value of the baseline angiogram in predicting ischemic events out to 1 year. As evidenced by the findings of the multivariable analysis and improved c statistics, angiographic characteristics provided important added prognostic value to the traditional clinical risk factors in predicting composite ischemia and MI at both 30 days and 1 year. Beyond the known clinical predictors, which included older age, nonuse of aspirin, biomarker elevation, STsegment deviation, lower baseline hemoglobin, history of PCI, renal insufficiency, and diabetes, 1-6 the angiographic predictors identified in this study can be broadly categorized as follows: (1) disease burden: number of diseased vessels and jeopardy score; (2) evidence of coronary tree calcification; (3) severity of disease: worst percent diameter stenosis; (4) lower LVEF evaluated by angiography; and (5) lesionspecific characteristics: eccentricity and thrombus. These 5 basic characteristics are all easily assessed by the operator at the time of diagnostic catheterization and were all important and consistent in predicting both 30-day and 1-year cumulative ischemic outcomes. In addition, LVEF as well as the severity of any lesion in the coronary tree at baseline was predictive of ischemic events beyond 30 days to 1 year (13% increase in composite ischemia odds beyond 30 days vs 8% overall increased 1-year cumulative ischemia odds for every 10% increase in diameter stenosis of any worse baseline lesion), implying that the angiogram provides prognostic value beyond procedure-related complications. There have been many reports regarding the adverse effects of complex lesion morphology and low LVEF as a harbinger of potential adverse events. 1, 2, 13, 14 The jeopardy score, which predicts cumulative mortality at 30 days and 1 year as well as 30-day MI, is a hybrid of lesion severity and myocardium at risk but is not necessarily a measure of disease burden. 12 It is important to note that in addition to LV function and the morphology of culprit lesions (such as lesion thrombus and eccentricity), the angiographic factors reflect a more global assessment of the burden of coronary disease and calcification, emphasizing the value of a systematic assessment of the entire coronary tree that is typically not undertaken in most interventional trials, but is 1 that would likely provide far more insight into patient outcomes compared with traditional lesion-specific characteristics. Furthermore, a number of angiographic scoring systems that predict outcomes have been proposed that are extremely complex. 15 The extent of coronary disease and calcification measured in the ACUITY trial is simple. Although there are no data regarding the core laboratory versus clinical site observer variability of these measures, these can be easily and rapidly implemented by the operator in the catheterization laboratory immediately after diagnostic catheterization but before coronary intervention.
The prevalence of multivessel disease was higher in ACUITY compared with previous reports assessing an early invasive strategy, likely a result of the lower threshold used to define CAD in ACUITY (diameter stenosis Ͼ30%) compared with earlier studies (diameter stenosis Ͼ50%). 9,16 -19 The prognostic significance of the extent of disease and 3-vessel CAD as a result of using this lower threshold on both 30-day and 1-year ischemic outcomes suggests that it may be more appropriate than the traditional 50% cutoff.
The severity and extent of coronary calcium was a significant predictor of 1-year composite ischemia, MI, and death, with evidence of an incremental risk of composite ischemia associated with increasing number of calcified vessels (Figure, B) . Angiographically moderate or severe calcification was found in 34.1% of patients, a higher rate than in some previous studies. 16 -19 The likely reason for this discrepancy is that, in the current study, all baseline angiograms were reviewed by an independent core laboratory for complete 3-vessel assessment of prespecified characteristics. Thus, the coronary calcification included in the assessment was not just at the culprit site but throughout the entire coronary tree. Radiographically detectable coronary artery calcium, which has been shown to be correlated with the total area of coronary artery plaque, signifies a greater extent of atherosclerotic disease and has been associated with a greater risk of coronary events. 20 -22 Although the identification of coronary artery calcification is limited by many factors, according to at least 1 intravascular ultrasound study, 23 angiographic calcification at a remote site in the coronary tree is a predictor of angiographically undetected target lesion calcium. In addition to indicating a greater extent of disease, the presence of angiographic calcification at the culprit site has been independently associated with a higher incidence of adverse clinical outcomes. 24 Culprit lesion calcification after PCI/ stent implantation has not been shown to predict restenosis if full expansion of the stent is obtained. 25, 26 However, extensive superficial calcification may impair luminal gain with coronary stenting owing to resistance to full expansion of the stent. This situation may lead to restenosis, stent thrombosis, or other suboptimal results, even with use of drug-eluting stents. [27] [28] [29] 
Limitations
There are several limitations to the present analysis. First, the ACUITY trial was not powered for subgroup analyses, and therefore these results should be considered exploratory. Second, results might have been affected by treatment bias, as the ACUITY trial was an open-label study. To mitigate these effects, every end point was adjudicated by an independent, blinded Clinical Events Committee that used source documents, and all core laboratories were blinded. Third, in ACUITY, nearly half of the patients were treated with PCI, 10% with CABG, and 30% with medical therapy. The ACUITY trial did not capture the reason for selection of medical therapy, whether because of mild disease or extensive coronary disease presumably unsuitable for revascularization. Because the study population was not exclusively a PCI population, we did not include post-PCI angiographic complications in the predictive model. Finally, the results of this study apply only to patients with non-ST-segment eleva-tion ACSs in whom coronary angiography in the first 72 hours was planned.
Conclusions
Among moderate-and high-risk ACS patients, beyond recognized clinical risk factors, the angiographic manifestations of LV dysfunction, extent of CAD burden, severity of disease, extent of calcification, and specific lesion characteristics are easily measured and add prognostic value for both 30-day and 1-year ischemic outcomes. This study emphasizes the importance of referring patients presenting with ACSs to diagnostic angiography for optimal risk stratification and appropriate management.
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